NDLI: Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Content Provider	Springer Nature Link
Author	Enkner, Franz Pichlhöfer, Bettina Zaharie, Alexandru Teodor Krunic, Milica Holper, Tina Maria Janik, Stefan Moser, Bernhard Schlangen, Karin Neudert, Barbara Walter, Karin Migschitz, Brigitte Müllauer, Leonhard
Copyright Year	2016
Abstract	Thymoma and thymic carcinoma are thymic epithelial tumors (TETs). We performed a molecular profiling to investigate the pathogenesis of TETs and identify novel targets for therapy. We analyzed 37 thymomas (18 type A, 19 type B3) and 35 thymic carcinomas. The sequencing of 50 genes detected nonsynonymous mutations in 16 carcinomas affecting ALK, ATM, CDKN2A, ERBB4, FGFR3, KIT, NRAS and TP53. Only two B3 thymomas had a mutation in noncoding regions of the SMARCB1 and STK11 gene respectively. Three type A thymomas harbored a nonsynonymous HRAS mutation. Fluorescence in situ hybridization detected in 38 % of carcinomas a CDKN2A, in 32 % a TP53 and in 8 % an ATM gene deletion, whereas only one B3 thymoma exhibited a CDKNA deletion, and none of the type A thymomas showed a gene loss. Sequencing of the total miRNA pool of 5 type A thymomas and 5 thymic carcinomas identified the C19MC miRNA cluster as highly expressed in type A thymomas, but completely silenced in thymic carcinomas. Furthermore, the miRNA cluster C14MC was downregulated in thymic carcinomas. Among non-clustered miRNAs, the upregulation of miR-21, miR-9-3 and miR-375 and the downregulation of miR-34b, miR-34c, miR-130a and miR-195 in thymic carcinomas were most significant. The expression of ALK, HER2, HER3, MET, phospho-mTOR, p16$^{INK4A}$, PDGFRA, PDGFRB, PD-L1, PTEN and ROS1 was investigated by immunohistochemistry. PDGFRA was increased in thymic carcinomas and PD-L1 in B3 thymomas and thymic carcinomas. In summary, our results reveal genetic differences between thymomas and thymic carcinomas and suggest potential novel targets for therapy.
Starting Page	551
Ending Page	564
Page Count	14
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	23
Issue Number	3
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2016-11-14
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Thymoma Thymic carcinoma Mutation miRNA Immunohistochemistry Cancer Research Oncology Pathology Immunology Biomedicine
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Cystic thymoma

Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions

Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma

Molecular events as targets of anticancer drug therapy

Genetic Alterations and Expression Pattern of CEACAM1 in Colorectal Adenomas and Cancers

Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma

Expression of Ephb2 and Ephb4 in breast carcinoma

The Missing Link in the Diagnostic Pathway of Prostate Cancer

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Similar Documents

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets

Cystic thymoma

Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions

Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma

Molecular events as targets of anticancer drug therapy

Genetic Alterations and Expression Pattern of CEACAM1 in Colorectal Adenomas and Cancers

Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma

Expression of Ephb2 and Ephb4 in breast carcinoma

The Missing Link in the Diagnostic Pathway of Prostate Cancer

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets